User profiles for Gamze Beydağı
 | Gamze BeydağıYeditepe Üniversitesi Verified email at yeditepe.edu.tr Cited by 19 |
[HTML][HTML] Initial Findings on the Use of [225Ac] Ac-DOTATATE Therapy as a Theranostic Application in Patients with Neuroendocrine Tumors
Objectives: This study aimed to evaluate the stability, safety, and efficacy of alpha-targeted
therapy with [225 Ac] Ac-DOTATATE in patients with grade 1/2 metastatic neuroendocrine …
therapy with [225 Ac] Ac-DOTATATE in patients with grade 1/2 metastatic neuroendocrine …
Clinical Experience with [225Ac] Ac-PSMA Treatment in Patients with [177Lu] Lu-PSMA–Refractory Metastatic Castration-Resistant Prostate Cancer
For patients with advanced-stage metastatic castration-resistant prostate cancer (mCRPC)
who do not respond to [ 177 Lu]Lu-PSMA therapy, there are limited treatment options. Clinical …
who do not respond to [ 177 Lu]Lu-PSMA therapy, there are limited treatment options. Clinical …
Prediction of clinically significant prostate cancer by [68 Ga]Ga-PSMA-11 PET/CT: a potential tool for selecting patients for active surveillance
Purpose In our study, our aim was to investigate the role of [ 68 Ga]Ga-PSMA-11 PET /CT
imaging in the diagnosis of clinically significant prostate cancer (csPCa) (ISUP GG 2 and higher…
imaging in the diagnosis of clinically significant prostate cancer (csPCa) (ISUP GG 2 and higher…
[HTML][HTML] Investigating Combination Therapy: The Role of Lutetium-177 PSMA-617 Radioligand Therapy and Androgen Receptor Pathway Inhibitors in Metastatic …
Background: The combination of Lutetium-177 (Lu-177) PSMA-617 radioligand therapy (RLT)
with androgen receptor pathway inhibitors (ARPIs) has shown promise in metastatic …
with androgen receptor pathway inhibitors (ARPIs) has shown promise in metastatic …
[HTML][HTML] Revision of the Histopathological Examination Following 68 Ga-DOTA-FAPI-04 PET/CT of a Breast Tumor Diagnosed as Invasive Ductal Carcinomatosis.
NA Selçuk, K Akçay, G Beydağı… - Molecular imaging …, 2024 - mirt.tsnmjournals.org
Neuroendocrine tumors (NETs) of the breast represent 1% of breast carcinomas. Histopathological
misinterpretation of breast NET is common. We present the case of a female patient …
misinterpretation of breast NET is common. We present the case of a female patient …
Alpha Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumors
G Beydağı, NA Selçuk, L Kabasakal - nukleertipseminerleri.org
Extensive use of peptide receptor radionuclide therapy has improved survival and quality of
life in patients with neuroendocrine tumor. Even though these results, treatment resistance …
life in patients with neuroendocrine tumor. Even though these results, treatment resistance …
Approach to a Mediastinal Parathyroid adenoma: A case report
O Sonmez, G Beydağı, K Akcay… - Endocrine …, 2023 - endocrine-abstracts.org
Ectopic mediastinal parathyroid adenoma is a rare cause of primary hyperparathyroidism (PHPT),
which is reported in 1-1.5% of patients. We present you a case of a 22-year old male, …
which is reported in 1-1.5% of patients. We present you a case of a 22-year old male, …
Revision of the histopathological examination following 68 Ga DOTA-FAPI-04 PET/CT of a Neuroendocrine breast tumor diagnosed as Invasive Ductal …
O Sonmez, K Akcay, G Beydağı, SN Alan… - Endocrine …, 2023 - endocrine-abstracts.org
Neuroendocrine tumors (NETs) of the breast are very rare. They represent less than 1% of
breast carcinomas. It is important to differentiate metastatic neuroendocrine neoplasia from …
breast carcinomas. It is important to differentiate metastatic neuroendocrine neoplasia from …
[CITATION][C] Nöroendokrin Tümörlerde Alfa Peptit Reseptör Radyonüklid Tedavi
G Beydağı, NA Selçuk, L Kabasakal
[CITATION][C] ORJINAL MAKALE
BVSMF Bozkurt, BPBÇÖ Uğur - jag.journalagent.com
… Emre Demirci, Nalan Alan Selçuk, Gamze Beydağı, Meltem Ocak, Türkay Toklu, Kaan
Akçay, Levent Kabasakal …
Akçay, Levent Kabasakal …